Abbott

Last updated April 7, 2026

Innovation Areas

Molecular diagnostics and brain biomarkers: AbbottRecent Research Landscape

Low-concentration biomarkers in complex fluids require integrated digital readout and amplification methods to achieve diagnostic sensitivity at the bedside.

What technical problems is Abbott addressing in Molecular diagnostics and brain biomarkers?

Nucleic acid amplification interference

(49)evidences

Conventional molecular diagnostic workflows suffer from high background noise, complex sample preparation requirements, and limited sensitivity for low-abundance viral targets.

Traumatic brain injury biomarker quantification

(121)evidences

Delayed or imprecise measurement of GFAP and UCH-L1 levels in blood prevents rapid, objective assessment of traumatic brain injury at the point of care.